Advertisement

Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization

  • Sarah Moussa
  • Siamak Ansari-Shahrezaei
  • Eva Smretschnig
  • Stefan Hagen
  • Kerstin Steindl-Kuscher
  • Ilse Krebs
  • Susanne Binder
Retinal Disorders

Abstract

Background

To evaluate contrast sensitivity (CS) using Pelli-Robson charts after intravitreal ranibizumab (IVR) (Lucentis, Novartis, Basel, Switzerland) or bevacizumab (IVB) (Avastin, Genentech, South San Francisco, California, USA) in eyes with myopic choroidal neovascularization (mCNV).

Methods

A retrospective review was performed of 17 consecutive patients treated with IVR (n = 10; 0.5 mg) or IVB (n = 7; 1.25 mg) for mCNV from July, 2006 with follow-ups through September, 2009. Re-treatment was performed at monthly or longer intervals if there was fluorescein leakage in fluorescein angiogram (FAG) and or apparent subretinal fluid in optical coherence tomography (OCT) persisted.

Results

CS improved by a mean of one letter at 1 month (n = 17; p = 0.32), four letters at 3 months (n = 17; p = 0.02), four letters at 6 months (n = 15; p = 0.01), five letters at 9 months (n = 14; p = 0.04) and six letters at 12 months (n = 13; p = 0.03). The mean number of IVR/IVB was 1.6/1.6, 2.6/2.3, 3.1/3.2, 4.1/4.2 and 4.5/4.6 at 1 month, 3 months, 6 months, 9 months, and 12 months, respectively.

Conclusions

Improvements in Pelli-Robson CS scores were observed during the first year after IVR/IVB in eyes with mCNV.

Keywords

Bevacizumab Myopic choroidal neovascularization Pelli-Robson contrast sensitivity Ranibizumab 

Notes

Conflicts of interest

The authors have no conflict of interests to declare.

Financial support

No financial support was provided for this study.

References

  1. 1.
    Arden GB (1978) The importance of measuring contrast sensitivity in case of visual disturbance. Br J Ophtalmol 62:198–209CrossRefGoogle Scholar
  2. 2.
    Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244PubMedGoogle Scholar
  3. 3.
    Elliott DB, Hurst MA, Weatherill J (1990) Comparing clinical tests of visual function in cataract with patient’s perceived visual disability. Eye 4:712–717PubMedGoogle Scholar
  4. 4.
    Haegerstrom-Portnoy G, Schneck ME, Lott LA, Brabyn JA (2000) The relation between visual acuity and other spatial vision measures. Optom Vis Sci 77:653–662CrossRefPubMedGoogle Scholar
  5. 5.
    Kuyk T, Elliott JL (1999) Visual factors and mobility in persons with age-related macular degeneration. J Rehabil Res Dev 36:303–312PubMedGoogle Scholar
  6. 6.
    Marron JA, Bailey IL (1982) Visual factors and orientation-mobility performance. Am J Optom Physiol Opt 59:413–426PubMedGoogle Scholar
  7. 7.
    Mones J, Rubin GS (2005) Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularization due to age-related macular degeneration. Eye 19:1142–1150CrossRefPubMedGoogle Scholar
  8. 8.
    Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, Tokoro T, Mocjizuki M (2003) Patchy atrophy and lacquer cracks predispose to development of choroidal neovascularization in pathological myopia. Br J Ophtalmol 87:570–573CrossRefGoogle Scholar
  9. 9.
    Owsley C (2003) Contrast Sensitivity. Ophtalmol Clin North Am 16:171–177CrossRefGoogle Scholar
  10. 10.
    Rubin GS (1988) Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vis Sci 2:169–177Google Scholar
  11. 11.
    Rubin GS, Roche KB, Prasado-Rao P, Fried LP (1994) Visual impairment and disability in older adults. Optom Vis Sci 71:750–760CrossRefPubMedGoogle Scholar
  12. 12.
    Rubin GS, Bandeen-Roche K, Huang GH, Munoz B, Schein OD, Fried LP, West SK (2001) The association of multiple visual impairments with self report visual disability: SEE project. Invest Ophthalm Vis Sci 42:64–72Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Sarah Moussa
    • 1
  • Siamak Ansari-Shahrezaei
    • 1
    • 2
    • 3
  • Eva Smretschnig
    • 1
  • Stefan Hagen
    • 1
    • 2
  • Kerstin Steindl-Kuscher
    • 1
  • Ilse Krebs
    • 1
    • 2
  • Susanne Binder
    • 1
    • 2
  1. 1.The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser SurgeryViennaAustria
  2. 2.Department of OphthalmologyRudolf Foundation ClinicViennaAustria
  3. 3.Department of OphthalmologyMedical University of GrazGrazAustria

Personalised recommendations